Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navlimetostat + Pembrolizumab + Chemotherapy in 1L Metastatic NSCLC with MTAP Deletion
NCT07063745Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2026
- Primary completion
- Aug 2031
- Modality
- Small Molecules
- Countries
- 34
01
Overview
A Phase 3 trial of navlimetostat in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Jan 2026; status: recruiting.
02
Drugs
navlimetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07063745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07063745.